GJCU yields 666.67% · ABBV yields 3.06%● Live data
📍 GJCU pulled ahead of the other in Year 1
Combined, GJCU + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GJCU + ABBV for your $10,000?
GJ Culture Group US, Inc. provides educational and other related services based on classical Chinese studies and culture. The company offers international study tours, which include the youth study tour series, adult study tour series, and themed study tour series of culture and art. It also provides lectures on classical studies; meditation courses; education and training services; and cultural events and art exhibitions. In addition, the company offers consulting and planning services to its contracted Chinese partners, including telephone or online consultation regarding market and research analysis of classical Chinese culture study in the United States for the business activities or international tour proposed by its Chinese partners, as well as online oral trainings to the staff of its Chinese business partners. It serves the Chinese-Americans, American youths, scholars, art collectors, and professional and corporate executives interested in learning about Chinese culture. The company was formerly known as Guojiang Cultural Industry US, Inc. and changed its name to GJ Culture Group US, Inc. in February 2019. GJ Culture Group US, Inc. was incorporated in 2018 and is based in Danville, California.
Full GJCU Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.